Aaron Goldberg

12PUBLICATIONS
66CO-AUTHORS
Gene and molecular therapyMedical infection agents (incl. prions)Medical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 29, 2026
Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.

|Dec 06, 2025
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.

Kuo-Kai Chin, Brian J Ball, Yasmin Abaza

|Oct 14, 2024
HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML.

Kuo-Kai Chin, Andriy Derkach, Christopher Famulare

|Jun 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.

Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis

|Jun 10, 2024
TP53 Y220C mutations in patients with myeloid malignancies.

Georgina Gener-Ricos, Jan P Bewersdorf, Sanam Loghavi

|Feb 07, 2024
Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.

Eunice S Wang, Aaron D Goldberg, Martin Tallman

Pageof 2

Frequent Collaborators

4 joint publications

Mark B Geyer

3 joint publications

Sheng F Cai

3 joint publications

Andriy Derkach

3 joint publications

Brian J Ball